TBIO Events
The 2nd 18th General Assembly of Taiwan Bio Industry Organization, co-organized by 資誠 (PwC Taiwan), was held on October 14, 2025 at the NTUH International Convention Center, where the event drew nearly 400 professionals from the biotech sector.
The day time forum featured insightful discussions on "Current Status and Trends in Global Digital Biomedicine" and "U.S. Reciprocal Tariffs and Most-Favored-Nation Drug Policy Analysis", and twi focus panel discussions on "The Value of Data and AI Applications in Biomedicine" and "Building Resilience in Taiwan's Biotech Financial Chain".
The evening gala dinner also featured distinguished speakers, including: Minister without Portfolio Chen Shih-chung, Executive Yuan, who in his opening speech expressed strong government confidence in the future of the biotech industry, highlighting that the "Healthy Taiwan Vision" represents a key national priority. Dr. Chiang Chih-kang, Director-General of the Taiwan Food and Drug Administration (TFDA), delivered a keynote titled "New Trends in Biomedical Product Development and Regulation Under the Healthy Taiwan Vision", stating that the TFDA, while ensuring safety, efficacy, and quality consistency, will also assist the industry through project-based guidance and diverse certification mechanisms, helping Taiwan's biomedical products and services enter the international market. Dr. Wang Chien-chuan, Vice President of the Chung-Hua Institution for Economic Research, discussed Taiwan's economic opportunities and challenges amid tariff and currency fluctuations. He argued that Trump's "reciprocal tariffs" are essentially a political tool to resolve U.S. debt issues by using trade as leverage. Hence, countries negotiating with Trump must focus not on democratic values, but on real bargaining chips.
The 2nd 18th General Assembly concluded successfully after the gala dinner. Our sincere thanks to all members for their continued support and participation!
The day time forum featured insightful discussions on "Current Status and Trends in Global Digital Biomedicine" and "U.S. Reciprocal Tariffs and Most-Favored-Nation Drug Policy Analysis", and twi focus panel discussions on "The Value of Data and AI Applications in Biomedicine" and "Building Resilience in Taiwan's Biotech Financial Chain".
The evening gala dinner also featured distinguished speakers, including: Minister without Portfolio Chen Shih-chung, Executive Yuan, who in his opening speech expressed strong government confidence in the future of the biotech industry, highlighting that the "Healthy Taiwan Vision" represents a key national priority. Dr. Chiang Chih-kang, Director-General of the Taiwan Food and Drug Administration (TFDA), delivered a keynote titled "New Trends in Biomedical Product Development and Regulation Under the Healthy Taiwan Vision", stating that the TFDA, while ensuring safety, efficacy, and quality consistency, will also assist the industry through project-based guidance and diverse certification mechanisms, helping Taiwan's biomedical products and services enter the international market. Dr. Wang Chien-chuan, Vice President of the Chung-Hua Institution for Economic Research, discussed Taiwan's economic opportunities and challenges amid tariff and currency fluctuations. He argued that Trump's "reciprocal tariffs" are essentially a political tool to resolve U.S. debt issues by using trade as leverage. Hence, countries negotiating with Trump must focus not on democratic values, but on real bargaining chips.
The 2nd 18th General Assembly concluded successfully after the gala dinner. Our sincere thanks to all members for their continued support and participation!